Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Repotrectinib - Turning Point Therapeutics

Next Previous
Drug Profile

Repotrectinib - Turning Point Therapeutics

Alternative Names: Augtyro; BMS-986472; Ropotrectinib; TPX 0005; ZL-2308

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TP Therapeutics
  • Developer Turning Point Therapeutics; ZAI Lab
  • Class Antineoplastics; Aza compounds; Fluorobenzenes; Ketones; Macrocyclic compounds; Pyrazoles; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Janus kinase-2 inhibitors; ROS1 protein inhibitors; Src-Family kinase inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer
  • Preregistration Solid tumours
  • Phase I/II CNS cancer; Lymphoma
  • Preclinical Multiple myeloma

Most Recent Events

  • 08 Apr 2024 Bristol Myers Squibb plans a phase I safety and pharmacokinetics study in healthy subjects in USA (PO) in April 2024 (NCT06352528)
  • 18 Mar 2024 Bristol Myers Squibb in collaboration with MedSIR plans a phase II REPOSE trial for Non small cell lung cancer in Austria in August 2024 (PO) (NCT06315010)
  • 22 Feb 2024 Repotrectinib receives priority review status for Solid tumours (In adolescents, In the elderly, Late-stage disease, Metastatic disease, In adults) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top